EirGen Pharma Product Dossier Eir-077 submitted in Canada

EirGen Pharma are pleased to report that the dossier for product Eir-077 was submitted to Health Canada in July2010. This product was successful developed as a treatment for advanced breast cancer and approval is anticipated early 2011.

Technical Director Tom Brennan stated that "this is a very significant achievement for us with this key product that passed clinical trial in February 2010. This builds on our product approval last year for another early-stage cancer treatment which is on sale in Canada since early 2010". Managing Director Patsy Carney stated that "another key milestone reached for EirGen with our second Canadian submission".

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.